IBM Research, Arctoris: AI-based drug discovery partnership
Arctoris and IBM Research have announced a partnership that involves investigating the application of artificial intelligence and automation technology to accelerate closed-loop molecule discovery. The collaborators reportedly plan to use IBM Research’s RXN for Chemistry online platform (which uses natural language processing architectures to automate synthetic chemistry) and automated platform for drug discovery research.
Thomas A. Fleming, Arctoris COO and co-founder, said, "The future of drug discovery is computational, with AI and robotics paving the way for better treatments to reach patients sooner. We are excited about partnering with IBM Research on a world-first closed loop drug discovery project bringing together two leaders in the field of AI and robotics-powered drug discovery; this collaboration will showcase how the combination of our unique technology platforms will lead to accelerated research based on better data enabling better decisions."
